Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Radiopharm Theranostics Limited ( (AU:RAD) ) just unveiled an announcement.
Radiopharm Theranostics Limited has announced a significant change in its substantial holding, with Lantheus Omega, LLC increasing its stake in the company. Following a share subscription agreement, Lantheus now controls 12.12% of the voting power in Radiopharm, up from 6.82%. This increase in shares, acquired at A$0.060 per share, underscores Lantheus’ growing investment in Radiopharm, potentially impacting the company’s strategic direction and market presence in the oncology sector.
More about Radiopharm Theranostics Limited
Radiopharm Theranostics Limited operates in the healthcare industry, focusing on the development and commercialization of radiopharmaceutical products for diagnostic and therapeutic purposes in the field of oncology.
YTD Price Performance: 35.00%
Average Trading Volume: 9,607,921
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$59.42M
See more insights into RAD stock on TipRanks’ Stock Analysis page.
